Search

Search
Ingredients Name

’ 에 대한 검색결과 (72)

  • ETC

Rosutatin Tab. 20mg

Active Ingredients
Rosuvastatin 20mg
Indications
1. Primary hypercholesterolemia (type Ⅱa including heterozygous familial hypercholesterolemia), complex hyperlipidemia (type Ⅱb): Dietary supplements if they cannot be controlled by diet and exercise 2. Adjuvant of diet or other lipid-lowering therapy (eg, LDL separation) for homozygous familial hypercholesterolemia 3. Delayed progression of atherosclerosis in patients with hypercholesterolemia by lowering total cholesterol and LDL-cholesterol to target levels 4. Dierary supplements to reduce chloesterol, LDL-cholesterol and Apo-B protein levels in patients aged 10 ~ 17 years (female at least one year after menarche) with heterozygous family hypercholesterolemia, which still meets the following criteria, despite the diet 1) LDL-cholesterol still exceeds 190 mg/dL (LDL-C>190 mg/dL) 2) LDL-cholesterol still exceeds 160 mg/dL (LDL-C>160 mg/dL), with a family history of early cardiovascular disease or at least two cardiovascular disease risk factors 5. Dietary supplements in patients with primary abnormal betalipoproteinemia (type III) 6. Reduced risk of cardiovascular disease: There is no clinical evidence of coronary heart disease, but men over 50 years of age and women over 60 years of age have a high sensitivity of C-reactive protein (hsCRP) of 2 mg/L and at least one additional cardiovascular risk factor (eg, high blood pressure, low HDL-cholesterol levels, smoking, or family history of early coronary heart disease); 1) Reduced risk of stroke 2) Reduced risk of myocardial infarction 3) Reduced risk of arterial angioplasty
  • ETC

Rosutatin Tab. 5mg

Active Ingredients
Rosuvastatin 5mg
Indications
1. Primary hypercholesterolemia (type Ⅱa including heterozygous familial hypercholesterolemia), complex hyperlipidemia (type Ⅱb): Dietary supplements if they cannot be controlled by diet and exercise 2. Adjuvant of diet or other lipid-lowering therapy (eg, LDL separation) for homozygous familial hypercholesterolemia 3. Delayed progression of atherosclerosis in patients with hypercholesterolemia by lowering total cholesterol and LDL-cholesterol to target levels 4. Dierary supplements to reduce chloesterol, LDL-cholesterol and Apo-B protein levels in patients aged 10 ~ 17 years (female at least one year after menarche) with heterozygous family hypercholesterolemia, which still meets the following criteria, despite the diet 1) LDL-cholesterol still exceeds 190 mg/dL (LDL-C>190 mg/dL) 2) LDL-cholesterol still exceeds 160 mg/dL (LDL-C>160 mg/dL), with a family history of early cardiovascular disease or at least two cardiovascular disease risk factors 5. Dietary supplements in patients with primary abnormal betalipoproteinemia (type III) 6. Reduced risk of cardiovascular disease: There is no clinical evidence of coronary heart disease, but men over 50 years of age and women over 60 years of age have a high sensitivity of C-reactive protein (hsCRP) of 2 mg/L and at least one additional cardiovascular risk factor (eg, high blood pressure, low HDL-cholesterol levels, smoking, or family history of early coronary heart disease); 1) Reduced risk of stroke 2) Reduced risk of myocardial infarction 3) Reduced risk of arterial angioplasty